CLDX - Celldex Therapeutics: Rising High With Room For Further Growth
2024-05-10 10:44:11 ET
Summary
- Celldex Therapeutics is a biopharmaceutical company with a strong pipeline of potential treatments.
- The company has a solid financial outlook, which is a positive factor for investors.
- If you respect the risks of investing based on phase 2 data, CLDX has a lot of promise yet unrealized.
Topline Summary
Celldex Therapeutics ( CLDX ) is a rare phoenix that long-time biotech investors will remember having a CLDX)%20today%20announced,glioblastoma%20will%20not%20reach%20statistical" > catastrophic data failure about a decade ago. If you had asked me back then what the prospects for the company were, I would have said that they seemed basically kaput. It was an extremely disappointing surprise, but over the years the company has clawed its way back, today sitting at a valuation of almost $3 billion as a phase 2 company....
Celldex Therapeutics: Rising High, With Room For Further Growth